Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia 2Leukemia, Myeloid, Chronic-Phase 1Bronchiolitis Obliterans Syndrome 1

Interventions

Cyclophosphamide 909Carboplatin 787pembrolizumab 744Paclitaxel 742Cisplatin 709Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 337Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Has results × BMS-833923 × Clear all
NCT01357655 2017-03-14

Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)

Bristol-Myers Squibb

Phase 2 Terminated
70 enrolled 8 charts
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia

NCT01218477 2016-06-17

Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)

Bristol-Myers Squibb

Phase 1/2 Completed
33 enrolled 18 charts
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡